ERa/PR crosstalk is altered in the context of the ERa Y537S mutation and contributes to endocrine therapy-resistant tumor proliferation.
ERa/PR crosstalk is altered in the context of the ERa Y537S mutation and contributes to endocrine therapy-resistant tumor proliferation. NPJ Breast Cancer. 2023 Nov 30; 9(1):96.